JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[PLATELET RICH PLASMA INJECTION AS TREATMENT FOR ROTATOR CUFF TENDINOPATHY AND AS AN AUGMENTATION FOR ROTATOR CUFF REPAIR].

Harefuah 2019 June
INTRODUCTION: Platelet rich plasma (PRP) intra-articular injections are gaining popularity worldwide. Albeit its vast application, its efficacy has not been proven unequivocally. This position statement was conducted for the Israeli Shoulder and Elbow Society and is intended to guide practitioners on treatment with PRP injections. Platelets secrete growth factors as part of their function which stimulates angiogenesis, cellular proliferation and tissue repair. Four main PRP subtypes exist: activated, non-activated, leucocyte-rich and leukocyte-poor. The function of leukocytes in PRP is not yet clearly understood and may locally cause harm. There are 3 main pathologies involving the shoulder and elbow in which PRP is being used: rotator cuff tendinopathy, rotator cuff tears and epicondylitis. Contraindications to PRP injection are infection, systemic disease presenting at the injection site, bone marrow pathology, thrombocytopenia, systemic steroids use and anticoagulant therapy. Most studies that explored the efficacy of PRP for rotator cuff tendinopathy failed to demonstrate any clinical benefit when compared to other non-operative treatments. Research shows that PRP injection improves rotator cuff tear healing when used as an augmentation to surgical repair, irrespective of tear size. Furthermore, high quality studies reported less pain in the early postoperative period with PRP augmentation in rotator cuff repair surgery but no significant changes to post-operative shoulder function. Larger studies were conducted on PRP injection to various joints which reported no side effects and approved its safety.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app